Headache & Migraine
Intranasal zavegepant safe and well tolerated in healthy adults
Telemedicine during COVID-19 pandemic highly appreciated
Brain Prize Lecture: Prof. Jes Olesen on migraine
Occipital nerve stimulation effective and safe in chronic cluster headache
Insights in drug-drug interactions facilitate rational polypharmacy
Rimegepant confers long-term improvements in MMDs
First real-world effectiveness data of erenumab is promising
Galcanezumab effective in patients with episodic or chronic cluster headache
Central effects and affected somatosensory processing with galcanezumab in migraine
Long-term safety and tolerability of atogepant in migraine
Largest genome-wide association study of migraine to date
Robust evidence that cluster headache has a genetic basis
Functional brainstem somatotopy of the trigeminal nerve during nociception
Morphological changes in cluster headache between attacks
Interictal pontine metabolism in migraine patients without aura
AI-enabled ECG algorithm predicts atrial fibrillation risk in migraine
Migraine may not be a risk factor for stroke
Predictors of health-related quality of life in cluster headache
Dry eye disease is more prevalent in migraine
Voice change and throat swelling are cranial autonomic symptoms in primary headache
Association between physical inactivity and headache disorders
Increased suicidal attempts and risks of ideation in medication-overuse headache
Telemedicine beneficial for headache care during the pandemic
Comparison of headaches after SARS-CoV-2 vaccination
Grey matter cortical changes in patients with persistent headache after COVID-19
Increased risk of cerebral venous thrombosis in COVID-19
Oral atogepant therapy trims number of days with migraines, headaches
Factors associated with decreased migraine attack risk
Pregnant migraine patients at higher risk of complications
Occipital nerve stimulation in drug-resistant cluster headache
Rhythmicity in primary headache disorders
Migraine not just a neurological problem for pregnant women
Long-term safety of atogepant as migraine prophylaxis
Headache disorders may up risk for temporomandibular disorders
Zavegepant nasal spray promises ultra-rapid relief from acute migraine
Mindfulness-based stress reduction tied to less disability, depression with migraine
Later school start time linked to fewer migraines in adolescents
Improvement of migraine using CGRP mAbs in a real-world setting
Similar treatment needs for high-frequency episodic and low-frequency chronic migraine
Nitroglycerin-induced cluster headache attacks characterised comprehensively
Remote electrical neuromodulation useful for adolescents with migraine
Concomitant preventive medication has no impact on efficacy of ubrogepant
No new cardiovascular safety concerns with long-term use of lasmiditan
Less medication use and fewer doctor visits with galcanezumab in treatment-resistant migraine
Real-world evidence reveals physicians’ perception of erenumab
Early initiation of lasmiditan improves migraine outcomes
Fremanezumab effective in patients with migraine and comorbid depression
Long-term onabotulinumtoxinA improves quality of life in migraine
Sustained shift in migraine status using galcanezumab
Worldwide survey shows substantial burden of migraine
Long-term efficacy and safety of fremanezumab in treatment-resistant migraine
Injection-site reactions with galcanezumab are mild and self-limiting
Migraine as a cyclical functional disorder
Reassuring real-world safety profile of 3 CGRP inhibitors
Long-term cardiovascular safety of erenumab
Real-world data for erenumab in Germany
Eptinezumab in chronic migraine and medication-overuse headache
Fremanezumab tolerability in cardiovascular patients with migraine
Effects of galcanezumab on health-related quality of life
Unmet needs and pipeline
The role of neurogenic inflammation in migraine
Lasmiditan in migraine patients with CV risk factors
Lasmiditan: rapid onset of efficacy in acute migraine
Galcanezumab reduces cluster headache frequency
Lessons learned from triptan therapy
